ProPhase Labs, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: PRPH · Form: DEF 14A · Filed: May 15, 2024 · CIK: 868278
| Field | Detail |
|---|---|
| Company | Prophase Labs, INC. (PRPH) |
| Form Type | DEF 14A |
| Filed Date | May 15, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0005, $1.4 billion, $50 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Stockholders, Director Election, Corporate Governance
TL;DR
<b>ProPhase Labs, Inc. will hold its 2024 Annual Meeting of Stockholders on June 20, 2024, to elect directors and conduct other business.</b>
AI Summary
ProPhase Labs, Inc. (PRPH) filed a Proxy Statement (DEF 14A) with the SEC on May 15, 2024. The 2024 Annual Meeting of Stockholders for ProPhase Labs, Inc. will be held on June 20, 2024, at 4:00 p.m. Eastern Time. The meeting will take place at the offices of Reed Smith LLP, 599 Lexington Avenue, 22nd Floor, New York, NY 10022. Stockholders are invited to attend and encouraged to vote their shares by proxy in advance. The agenda includes the election of four director nominees to serve until the 2025 Annual Meeting. ProPhase Labs, Inc. is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
For investors and stakeholders tracking ProPhase Labs, Inc., this filing contains several important signals. This filing is a definitive proxy statement (DEF 14A), indicating it contains important information for shareholders regarding the upcoming annual meeting and voting procedures. The meeting's agenda includes the election of directors, a key governance activity that allows shareholders to influence the company's leadership and strategic direction.
Risk Assessment
Risk Level: low — ProPhase Labs, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.
Analyst Insight
Shareholders should review the proxy materials carefully to understand the director nominees and any other proposals before casting their votes.
Key Numbers
- June 20, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
- 4:00 p.m. Eastern Time — Annual Meeting Time (Time the 2024 Annual Meeting of Stockholders will commence.)
- 4 — Director Nominees (Number of director nominees to be elected at the meeting.)
Key Players & Entities
- ProPhase Labs, Inc. (company) — Registrant and filer of the proxy statement.
- Ted Karkus (person) — Chairman of the Board of Directors and Chief Executive Officer.
- Reed Smith LLP (company) — Location of the Annual Meeting.
- June 20, 2024 (date) — Date of the Annual Meeting.
- 2024 (date) — Year of the Annual Meeting.
- 2025 (date) — Year of the subsequent Annual Meeting.
FAQ
When did ProPhase Labs, Inc. file this DEF 14A?
ProPhase Labs, Inc. filed this Proxy Statement (DEF 14A) with the SEC on May 15, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ProPhase Labs, Inc. (PRPH).
Where can I read the original DEF 14A filing from ProPhase Labs, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ProPhase Labs, Inc..
What are the key takeaways from ProPhase Labs, Inc.'s DEF 14A?
ProPhase Labs, Inc. filed this DEF 14A on May 15, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for ProPhase Labs, Inc. will be held on June 20, 2024, at 4:00 p.m. Eastern Time.. The meeting will take place at the offices of Reed Smith LLP, 599 Lexington Avenue, 22nd Floor, New York, NY 10022.. Stockholders are invited to attend and encouraged to vote their shares by proxy in advance..
Is ProPhase Labs, Inc. a risky investment based on this filing?
Based on this DEF 14A, ProPhase Labs, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.
What should investors do after reading ProPhase Labs, Inc.'s DEF 14A?
Shareholders should review the proxy materials carefully to understand the director nominees and any other proposals before casting their votes. The overall sentiment from this filing is neutral.
How does ProPhase Labs, Inc. compare to its industry peers?
ProPhase Labs, Inc. operates within the Pharmaceutical Preparations industry, a sector focused on the development and manufacturing of medicinal drugs.
Are there regulatory concerns for ProPhase Labs, Inc.?
The company is subject to the Securities Exchange Act of 1934, specifically Rule 14a-101 concerning proxy statements for shareholder meetings.
Risk Factors
- Filing Requirements [low — regulatory]: The company must comply with SEC regulations for filing proxy statements (DEF 14A) and conducting shareholder meetings.
Industry Context
ProPhase Labs, Inc. operates within the Pharmaceutical Preparations industry, a sector focused on the development and manufacturing of medicinal drugs.
Regulatory Implications
The company is subject to the Securities Exchange Act of 1934, specifically Rule 14a-101 concerning proxy statements for shareholder meetings.
What Investors Should Do
- Review the full proxy statement for details on director nominees and their qualifications.
- Understand the voting procedures and deadlines for submitting proxies.
- Consider attending the annual meeting or voting by proxy to exercise shareholder rights.
Key Dates
- 2024-06-20: Annual Meeting of Stockholders — Election of directors and other business.
Glossary
- DEF 14A
- Definitive Proxy Statement filed with the SEC. (Provides formal notice and details of matters to be voted on at a company's annual meeting.)
- Proxy Statement
- A document filed by a company with the SEC that contains information that shareholders need to make informed decisions about matters presented at a shareholder meeting. (Essential for shareholders to understand proposals and director nominees before voting.)
Year-Over-Year Comparison
This is the initial filing for the 2024 Annual Meeting of Stockholders; no prior filing for this specific event is referenced.
Filing Stats: 4,820 words · 19 min read · ~16 pages · Grade level 12.2 · Accepted 2024-05-15 16:05:38
Key Financial Figures
- $0.0005 — Company’s common stock, par value $0.0005 per share, that you own as of the close
- $1.4 billion — as sold to GlaxoSmithKline plc for over $1.4 billion. Mr. Karkus has twenty-five years of ex
- $50 million — eded in selling the Cold-EEZE brand for $50 million to Mylan, a multibillion-dollar pharmac
Filing Documents
- formdef14a.htm (DEF 14A) — 490KB
- formdef14a_001.jpg (GRAPHIC) — 4KB
- formdef14a_002.jpg (GRAPHIC) — 27KB
- formdef14a_003.jpg (GRAPHIC) — 28KB
- proxy_001.jpg (GRAPHIC) — 595KB
- proxy_002.jpg (GRAPHIC) — 486KB
- 0001493152-24-019839.txt ( ) — 2061KB
SECURITY OWNERSHIP
SECURITY OWNERSHIP 32 Audit Committee Report 33 Audit and Non-Audit Fees 34 PROPOSAL 2 - RATIFICATION OF THE APPOINTMENT OF INDEPENDENT AUDITORS 35 OTHER INFORMATION 36 Attending the Annual Meeting 36 Stockholder Proposals 36 Expenses and Solicitation 37 Householding of Proxy Materials 37 Other Business 37 4 ProPhase Labs, Inc. 711 Stewart Avenue, Suite 200 Garden PROXY QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND THE ANNUAL MEETING Q: Why am I receiving these materials? A: The Board of Directors (the “Board”) of ProPhase Labs, Inc. (the “Company,” “we,” “our,” or “us,” as the context requires) is providing this proxy statement (this “Proxy Statement”) to solicit your proxy in connection with the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), which will be held at the offices of Reed Smith LLP, located at 599 Lexington Avenue, 22nd Floor, New York, NY 10022, on Thursday, June 20, 2024, at 4:00 p.m., Eastern Time. The Board is requesting your vote on the proposals described in this Proxy Statement. This Proxy Statement and the Notice of Annual Meeting, along with the accompanying proxy card, or voting instruction form, as applicable, and the 2023 Annual Report are being mailed to stockholders on or about May 21,2024. Q: Who is soliciting the proxies? A: We are soliciting proxies in the form enclosed on behalf of the Board. Our Board has selected Ted Karkus and Jed A. Latkin (the “Named Proxies”) to vote all shares for which the Company has been appointed to act as proxy at the Annual Meeting. The Named Proxies will vote any properly executed proxy, if received in time and not revoked, at the Annual Meeting in accordance with your directions. The Named Proxies will vote any signed proxy that fails to specify a choice on any proposal to be acted